FUNDAMENTALS · Fundamentals · US Healthcare

Abbott Laboratories (ABT) Fundamentals 2026 — P/E 32.4x, Revenue Analysis | SniperIQ

Abbott Laboratories (ABT) is a US-listed Healthcare company in Medical - Devices with a market capitalization of

75.3B, trading at
00.64 on the NYSE. This SniperIQ fundamentals page covers Abbott Laboratories's valuation (P/E 32.4x, P/B 3.4x), profitability (net margin 11.6%), revenue ($44.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
75.3B
P/E (TTM)32.4x
Net Margin11.6%
Revenue (FY25)$44.3B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Abbott Laboratories's market cap?

Abbott Laboratories (ABT) has a market capitalization of approximately

75.3B, trading at
00.64 on the NYSE. Market cap moves with the live share price.

What is Abbott Laboratories's P/E ratio?

Abbott Laboratories's trailing twelve-month P/E ratio is 32.4x, with a price-to-book (P/B) of 3.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Abbott Laboratories?

Abbott Laboratories runs a net profit margin of 11.6%, a gross margin of 56.8%, and an operating margin of 17.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Abbott Laboratories generate?

Abbott Laboratories reported revenue of $44.3B for fiscal year 2025, with net income of $6.5B and earnings per share (EPS) of 3.74. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Abbott Laboratories pay a dividend?

Abbott Laboratories offers a trailing dividend yield of about 2.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Abbott Laboratories financially healthy?

Abbott Laboratories carries a debt-to-equity ratio of 0.65x and a current ratio of 1.39x, with a market beta of 0.61. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Abbott Laboratories a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Abbott Laboratories (ABT) the key facts are: market cap

75.3B, P/E 32.4x, revenue $44.3B, 52-week range 81.97-137.49. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Abbott Laboratories's full fundamentals live

Get Abbott Laboratories's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Chong Kun Dang Holdings (001630) fundamentals · AS ONE (7476) fundamentals · REYON Pharmaceutical (102460) fundamentals · Kissei Pharmaceutical (4547) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons